STOCK TITAN

Medigus Ltd. American Depositary Share Stock Price, News & Analysis

MDGS Nasdaq

Welcome to our dedicated page for Medigus Ltd. American Depositary Share news (Ticker: MDGS), a resource for investors and traders seeking the latest updates and insights on Medigus Ltd. American Depositary Share stock.

Medigus Ltd. (MDGS) pioneers minimally invasive endoscopic solutions for gastrointestinal disorders, with its flagship SRS system transforming GERD treatment. This dedicated news hub provides investors and medical professionals with timely updates on the company’s technological advancements, regulatory milestones, and strategic partnerships.

Access comprehensive coverage of Medigus’ developments including product launches, clinical trial results, financial performance, and OEM manufacturing initiatives. Our curated repository ensures stakeholders stay informed about innovations in endoscopic stapling systems, ultrasonic alignment technologies, and collaborative healthcare projects.

Key updates feature progress in endoluminal procedures, manufacturing expansions, and intellectual property achievements. Regular updates include earnings reports, executive leadership changes, and research breakthroughs that underscore Medigus’ position in medical device innovation.

Bookmark this page for direct access to official press releases and objective analysis of Medigus’ contributions to minimally invasive surgery. Check regularly for verified updates on the company’s progress in redefining endoscopic intervention standards and expanding global healthcare partnerships.

Rhea-AI Summary

Medigus Ltd. announced the closing of an underwritten public offering of 3,659,735 American Depositary Shares (ADSs) at $2.30 each, raising approximately $8.4 million in gross proceeds. The funds are intended for working capital and general corporate purposes. The underwriter holds a 15% option to purchase additional ADSs, potentially increasing gross proceeds to about $9.6 million. This offering is conducted under an effective registration statement with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
-
Rhea-AI Summary

Medigus Ltd. has announced a public offering of 3,659,735 American Depositary Shares (ADSs) priced at $2.30 each, aiming to raise approximately $8.4 million before expenses. The proceeds will be used for working capital and corporate purposes. The underwriter has a 15% over-allotment option, potentially increasing total gross proceeds to $9.6 million. The offering is expected to close around January 13, 2021, following standard conditions. Aegis Capital Corp. is the sole bookrunner for this offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.38%
Tags
-
Rhea-AI Summary

Medigus Ltd. (Nasdaq: MDGS) announced plans for an underwritten public offering of American Depositary Shares (ADSs). The offering includes an option for underwriters to buy an additional 15% to cover over-allotments. Proceeds will be utilized for working capital and corporate purposes. The offering's completion is contingent on market conditions, with no guarantees on its size or terms. Aegis Capital Corp. is the sole bookrunner. This offering follows an effective registration statement filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Medigus Ltd. (Nasdaq: MDGS) announced an agreement to acquire the intellectual property and know-how for a wireless robotic charging pad for electric vehicles. The provisional patent allows for automatic self-alignment during charging. Medigus will pay $75,000 for the rights and plans to invest an additional $150,000 in technology development. This initiative aims to expand Medigus' electric vehicle operations and will be consolidated under a new subsidiary.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.04%
Tags
none
-
Rhea-AI Summary

Medigus Ltd. (Nasdaq: MDGS) has successfully acquired a controlling interest in Smart Repair Pro, Inc. and Purex, Corp, e-commerce companies showing remarkable growth. In 2020, these companies reported a revenue increase of over 214%, reaching approximately $2.2 million compared to $0.7 million in 2019. Medigus now owns around 50.01% of each company's share capital. Smart Repair Pro plans to launch a new brand and product line, aiming to expand its sales model with a direct online store.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
none
-
Rhea-AI Summary

Medigus Ltd. (MDGS) announced that the underwriter of its public offering has fully exercised their option to purchase an additional 1,064,774 American Depositary Shares (ADSs) at $1.83 each. This brings total gross proceeds to approximately $14.93 million before expenses. The offering was made under an F-1 registration statement filed with the SEC. Aegis Capital Corp. acted as the sole bookrunner for this offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
none
Rhea-AI Summary

Medigus Ltd. (Nasdaq:MDGS) announced that its subsidiary ScoutCam is collaborating with the Israeli Air Force on three development projects. These involve deploying advanced micro-cameras to enhance maintenance and flight safety for unmanned aerial vehicles (UAVs) and helicopters. The integration of Artificial Intelligence aims to facilitate predictive maintenance, potentially reducing costs and improving safety. CEO Yaron Silberman highlighted that the global market for helicopters could be around $250 million annually, with significant opportunities in the fast-growing UAV sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
none
-
Rhea-AI Summary

Medigus Ltd. (Nasdaq:MDGS) announced the completion of Amazon's regulatory processes for Smart Repair Pro, Inc. to launch its store in Singapore. This marks the company's expansion into a new market, following its recent approval to operate in Australia, the UK, and several European nations. Furthermore, Medigus intends to acquire a controlling interest in Smart Repair Pro and Purex, Inc., expecting combined revenues of approximately $3 million for 2020 with a 35% net profit margin. The closing of these transactions is subject to customary conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
none
-
Rhea-AI Summary

Medigus Ltd. (Nasdaq: MDGS) has successfully closed a public offering of 7,098,491 American Depositary Shares (ADSs) at $1.83 each, generating gross proceeds of approximately $13 million. The funds will be utilized for working capital and general corporate purposes. Additionally, the underwriter has a 45-day option to purchase 15% more ADSs for over-allotments. This offering was made under an effective registration statement filed with the U.S. SEC. Aegis Capital Corp. served as the sole bookrunner for the transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
Rhea-AI Summary

Medigus Ltd. (Nasdaq: MDGS) announced a public offering of 7,098,491 American Depositary Shares at $1.83 each, aiming to raise approximately $13 million before expenses. The funds will be utilized for working capital and general corporate purposes. The offering includes a 45-day option for the underwriter to purchase an additional 15% of the ADSs. This offering is part of an effective registration statement with the SEC and is expected to close around December 4, 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.21%
Tags

FAQ

What is the current stock price of Medigus Ltd. American Depositary Share (MDGS)?

The current stock price of Medigus Ltd. American Depositary Share (MDGS) is $2.36 as of June 11, 2024.

What is the market cap of Medigus Ltd. American Depositary Share (MDGS)?

The market cap of Medigus Ltd. American Depositary Share (MDGS) is approximately 4.5M.
Medigus Ltd. American Depositary Share

Nasdaq:MDGS

MDGS Rankings

MDGS Stock Data

4.47M
28.42M
0.29%
0.22%
Medical Devices
Healthcare
Link
Israel
Tel Aviv